TRMLTourmaline Bio, Inc.

TRML Stock Price, Valuation & Chart | Tourmaline Bio, Inc.

Compare

$47.980+0.00 (+0.00%)

At close · 28 Oct 2025, 08:00 pm

Sector: Healthcare Industry: Biotechnology TRML intrinsic value Is TRML overvalued or undervalued

Overview Financials Dividends Ratios

TRML Historical price chart

TRML Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.23B

PE Ratio-13.95

EPS-3.44

Trading Volume783.73K

Today's High/Low47.98/47.98

Dividend Yield0.00

52 Week High/Low48.27/11.56

Shares Outstanding25.69M

TRML Financial Statement

TRML Analyst ratings

TRML Analysis & performance metrics

TRML Company profile

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies…

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

TRML Management team

Name

Position

Ryan Robinson CPACFO

Chief Financial Officer & Treasurer

Kevin B. Johnson M.B.A., Ph.D.

Chief Regulatory Officer

Sandeep C. Kulkarni M.D.CEO

Co-Founder, Chief Executive Officer & Director

Susan Dana Jones Ph.D.CTO

Chief Technology Officer

Gerhard Hagn Pharm.D.

Senior Vice President and Head of Commercial & Business Development

Kristine Erickson O.D., Ph.D.

Vice President & TA Head of Ophthalmology, Medical Research

Dora Rau

Senior Vice President & Head of Quality

W. Bradford Middlekauff J.D.

Chief Business Officer, General Counsel & Corporate Secretary

Name

Position

Ryan Robinson CPACFO

Chief Financial Officer & Treasurer

Kevin B. Johnson M.B.A., Ph.D.

Chief Regulatory Officer

Sandeep C. Kulkarni M.D.CEO

Co-Founder, Chief Executive Officer & Director

Susan Dana Jones Ph.D.CTO

Chief Technology Officer

Gerhard Hagn Pharm.D.

Senior Vice President and Head of Commercial & Business Development

Kristine Erickson O.D., Ph.D.

Vice President & TA Head of Ophthalmology, Medical Research

Dora Rau

Senior Vice President & Head of Quality

W. Bradford Middlekauff J.D.

Chief Business Officer, General Counsel & Corporate Secretary

Management Team

Ryan Robinson CPACFO

Chief Financial Officer & Treasurer

Kevin B. Johnson M.B.A., Ph.D.

Chief Regulatory Officer

Sandeep C. Kulkarni M.D.CEO

Co-Founder, Chief Executive Officer & Director

Susan Dana Jones Ph.D.CTO

Chief Technology Officer

Gerhard Hagn Pharm.D.

Senior Vice President and Head of Commercial & Business Development

Kristine Erickson O.D., Ph.D.

Vice President & TA Head of Ophthalmology, Medical Research

Dora Rau

Senior Vice President & Head of Quality

W. Bradford Middlekauff J.D.

Chief Business Officer, General Counsel & Corporate Secretary

Management

Ryan Robinson CPACFO

Chief Financial Officer & Treasurer

Kevin B. Johnson M.B.A., Ph.D.

Chief Regulatory Officer

Sandeep C. Kulkarni M.D.CEO

Co-Founder, Chief Executive Officer & Director

Susan Dana Jones Ph.D.CTO

Chief Technology Officer

Gerhard Hagn Pharm.D.

Senior Vice President and Head of Commercial & Business Development

Kristine Erickson O.D., Ph.D.

Vice President & TA Head of Ophthalmology, Medical Research

Dora Rau

Senior Vice President & Head of Quality

W. Bradford Middlekauff J.D.

Chief Business Officer, General Counsel & Corporate Secretary

Total 8 executives

TRML Frequently asked questions

What is Tourmaline Bio, Inc. (TRML) Stock Price?

Current stock price of Tourmaline Bio, Inc. (TRML) stock is $47.980. The stock price is +0.00% higher in the session. The intraday range can be seen from this page. Volume of Tourmaline Bio, Inc. (TRML) stock is 783.73K.

Last updated at 28 Oct 2025, 08:00 pm.

Why is the Tourmaline Bio, Inc. (TRML) stock price going up or down today?

The stock price of Tourmaline Bio, Inc. (TRML) can change with earnings, company news, and overall market sentiment. Tourmaline Bio, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Tourmaline Bio, Inc. stock expensive at its current price?

Whether Tourmaline Bio, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for TRML on this page is -13.95. EPS on this page is -3.44. Compare those figures with peers and growth expectations before deciding if the current Tourmaline Bio, Inc. price is justified.

How has the stock price of Tourmaline Bio, Inc. (TRML) performed historically?

Historical performance for Tourmaline Bio, Inc. (TRML) is shown on the price chart on this page. Review multi-period moves alongside volume to see how TRML reacted to past earnings and market events.

Should I buy Tourmaline Bio, Inc. (TRML) stock, at this price?

Buying Tourmaline Bio, Inc. (TRML) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.